Despite the CFO's stock sale, the company maintains a bullish outlook with projected 25% revenue growth to $630 million in fiscal 2026, expected swing to profitability in 2027, and significant upside potential from the Epioxa product which could generate over $1 billion in revenue by 2030. The non-discretionary nature of the sale under a pre-established trading plan mitigates bearish concerns.
Exceptional 32% YoY revenue growth to $507.4M, pioneering MIGS technology now industry standard, promising new Epioxa product with $1B+ revenue potential by 2030, strong iDose platform driving U.S. growth, and expected 25% sales growth to $630M in 2026 with narrowing losses to $56M. High growth potential justifies premium valuation despite current unprofitability.
Articles that tag GKOS but are mainly about other companies.
Channeling strong revenue growth into R&D with five novel therapeutic platforms and 13 publicly disclosed programs in ophthalmology. Sequential R&D increase of $8 million in Q2 demonstrates commitment to clinical development and pipeline expansion while improving operating leverage, positioning for successive product cycles.
Developing GLK-302 for presbyopia treatment, participating in the expanding therapeutic landscape with an emerging device candidate.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
